These risks and
uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships,
uncertainty regarding potential future deterioration
in the
market for auction rate securities which could result
in additional
permanent impairment charges, our ability to develop and
market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified
in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time
in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
«We appreciate NYPSC addressing near term
uncertainty in the
market by passing this stop - gap measure, and we urge the Commission to move quickly
in establishing a more
permanent solution until the new system [VDER Phase Two] is set,» said Brandon Smithwood, Policy Director for the Coalition for Community Solar Access.